{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:58:02Z","timestamp":1768705082612,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ygyno.2017.08.026","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T09:50:05Z","timestamp":1505901005000},"page":"276-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer"],"prefix":"10.1016","volume":"147","author":[{"given":"G.","family":"Rustin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Micha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Hannah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.08.026_bb0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.ygyno.2017.08.026_bb0015","doi-asserted-by":"crossref","first-page":"vii218","DOI":"10.1093\/annonc\/mdq377","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2017.08.026_bb0020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/fon.12.112","article-title":"The changing landscape of therapeutic strategies for recurrent ovarian cancer","volume":"8","author":"Baumann","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2017.08.026_bb0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11912-013-0367-8","article-title":"Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor","volume":"16","author":"Alemany","year":"2014","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0035","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-014-2577-7","article-title":"Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models","volume":"74","author":"Hoch","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/1078-0432.CCR-12-1201","article-title":"Multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors","volume":"19","author":"Jameson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [14C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/1011-4564.131897","article-title":"Topoisomerase I inhibitor suppress tumor growth in chemoresistant ovarian cancer-initiating cells","volume":"34","author":"Wang","year":"2014","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0055","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.2012.45.1278","article-title":"Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant\/refractory epithelial ovarian cancer","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"suppl","key":"10.1016\/j.ygyno.2017.08.026_bb0060","article-title":"The role of NKTR-102 in women with platinum resistant\/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD)","volume":"29","author":"Garcia","year":"2011","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.08.026_bb0075","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0080","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/cncr.26569","article-title":"Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study","volume":"118","author":"Hensley","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.08.026_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr. Oncol."},{"issue":"suppl","key":"10.1016\/j.ygyno.2017.08.026_bb0090","article-title":"A phase III study of Doxil\/Caelyx versus paclitaxel in platinum-treated, taxane na\u00efve relapsed ovarian cancer","volume":"21","author":"O'Byrne","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0095","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0100","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0105","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.026_bb0110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817312647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817312647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T20:43:16Z","timestamp":1750884196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817312647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0090825817312647"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}